Mather Group LLC. Grows Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Mather Group LLC. increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 172.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 461 shares of the medical research company’s stock after buying an additional 292 shares during the quarter. Mather Group LLC.’s holdings in Bio-Rad Laboratories were worth $151,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Principal Financial Group Inc. grew its holdings in shares of Bio-Rad Laboratories by 95.6% during the third quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company’s stock worth $14,836,000 after buying an additional 21,669 shares during the last quarter. Mawer Investment Management Ltd. grew its holdings in shares of Bio-Rad Laboratories by 63.0% during the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock worth $72,900,000 after buying an additional 84,237 shares during the last quarter. Verition Fund Management LLC grew its holdings in shares of Bio-Rad Laboratories by 193.3% during the third quarter. Verition Fund Management LLC now owns 3,470 shares of the medical research company’s stock worth $1,161,000 after buying an additional 2,287 shares during the last quarter. Diversified Trust Co purchased a new position in shares of Bio-Rad Laboratories during the fourth quarter worth about $958,000. Finally, Louisiana State Employees Retirement System boosted its holdings in Bio-Rad Laboratories by 341.7% in the 3rd quarter. Louisiana State Employees Retirement System now owns 5,300 shares of the medical research company’s stock valued at $1,773,000 after purchasing an additional 4,100 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Price Performance

BIO stock opened at $341.69 on Friday. The firm has a 50 day moving average of $341.16 and a 200-day moving average of $336.46. Bio-Rad Laboratories, Inc. has a 12-month low of $262.12 and a 12-month high of $387.99. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The company has a market cap of $9.57 billion, a price-to-earnings ratio of -12.50 and a beta of 0.90.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BIO. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Citigroup lifted their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $394.20.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.